Abstract
The Dutch on-the-road driving test is a standardized test, conducted on a public highway in actual traffic. Participants are instructed to drive for 100-km, while maintaining a steady lateral position and constant speed (95 km/h). Standard Deviation of Lateral Position (SDLP) is the primary outcome measure of the test. This review summarizes the results of 30 years of Dutch on-the-road driving research applying this test. Many central nervous system (CNS)-drugs show dose-dependent impairment on the driving test, expressed in significantly elevated SDLP values relative to placebo. This review discusses several determinants of drug-related driving impairment, including those related to the drug, its use, driver demographics, and the environment. Implications for study design, and limitations of the current methodology are discussed, as well as future challenges to improve the methodology. Overall, the on-the-road driving test has proven to be a reliable and sensitive test to assess the potential effects of CNS drugs on driving ability.
Keywords: Driving, safety, SDLP, on-the-road test, CNS-drugs, anxiolytics, hypnotics, triazolam, flurazepam, benzodiazepines, PLACEBO, sleepiness, methylphenidate, neurobehavioral, tolerance
Current Psychopharmacology
Title: Thirty Years of Dutch Drugs and Driving Research: Strengths and Limitations of the On-The-Road Highway Driving Test and Future Challenges
Volume: 1
Author(s): Joris C. Verster and Thomas Roth
Affiliation:
Keywords: Driving, safety, SDLP, on-the-road test, CNS-drugs, anxiolytics, hypnotics, triazolam, flurazepam, benzodiazepines, PLACEBO, sleepiness, methylphenidate, neurobehavioral, tolerance
Abstract: The Dutch on-the-road driving test is a standardized test, conducted on a public highway in actual traffic. Participants are instructed to drive for 100-km, while maintaining a steady lateral position and constant speed (95 km/h). Standard Deviation of Lateral Position (SDLP) is the primary outcome measure of the test. This review summarizes the results of 30 years of Dutch on-the-road driving research applying this test. Many central nervous system (CNS)-drugs show dose-dependent impairment on the driving test, expressed in significantly elevated SDLP values relative to placebo. This review discusses several determinants of drug-related driving impairment, including those related to the drug, its use, driver demographics, and the environment. Implications for study design, and limitations of the current methodology are discussed, as well as future challenges to improve the methodology. Overall, the on-the-road driving test has proven to be a reliable and sensitive test to assess the potential effects of CNS drugs on driving ability.
Export Options
About this article
Cite this article as:
C. Verster Joris and Roth Thomas, Thirty Years of Dutch Drugs and Driving Research: Strengths and Limitations of the On-The-Road Highway Driving Test and Future Challenges, Current Psychopharmacology 2012; 1 (1) . https://dx.doi.org/10.2174/2211556011201010097
DOI https://dx.doi.org/10.2174/2211556011201010097 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiac Effect of Cholinesterase Inhibitors Used in Alzheimers Disease - from Basic Research to Bedside
Current Alzheimer Research Novel Systemic Drugs for Cutaneous T-Cell Lymphoma
Recent Patents on Anti-Cancer Drug Discovery Fibromyalgia
Current Rheumatology Reviews MCI Patients in Europe: Medication and Comorbidities. The DESCRIPA Study
Current Alzheimer Research Effects of Nicotine on the Cardiovascular System
Vascular Disease Prevention (Discontinued) Neurokinin-1 Receptor Antagonists in Lung Cancer Therapy
Letters in Drug Design & Discovery A Comparative Analysis of Brain and Plasma Aβ Levels in Eight Common Non-Transgenic Mouse Strains: Validation of a Specific Immunoassay for Total Rodent Aβ
Current Alzheimer Research ERRATUM
Current Neuropharmacology Age-Related Sleep Disruption and Reduction in the Circadian Rhythm of Urine Output: Contribution to Nocturia?
Current Aging Science Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay
Current Drug Targets Targeting SREBP-1-driven Lipid Metabolism to Treat Cancer
Current Pharmaceutical Design Mini-Mental Parkinson (MMP) as a Dementia Screening Test: Comparison with the Mini-Mental State Examination (MMSE)
Current Aging Science Special Issue on Medical Imaging Technologies for IoT Based Wireless Patient Monitoring
Current Medical Imaging Techniques to Investigate Neuronal Mitochondrial Function and its Pharmacological Modulation
Current Drug Targets Establishment of Conditionally Immortalized Cell Lines with Specific Functions and its Application to Differential Gene Expression Analysis by DNA Microarray Technology
Current Pharmaceutical Analysis Editorial (Hot Topic: Neurodegeneration: The First IBRO-Middle East Neuroscience Conference)
Current Alzheimer Research Gene Delivery by Functional Inorganic Nanocarriers
Recent Patents on DNA & Gene Sequences Molecular Modeling Studies of Anti-Alzheimer Agents by QSAR, Molecular Docking and Molecular Dynamics Simulations Techniques
Medicinal Chemistry Metformin - The Drug for the Treatment of Autoimmune Diseases; A New Use of a Known Anti-Diabetic Drug
Current Topics in Medicinal Chemistry Physiologic Responses in Anxiety
Current Psychiatry Reviews